Outcomes of C1–2 joint injections
Received 18 June 2017
Accepted for publication 15 August 2017
Published 18 September 2017 Volume 2017:10 Pages 2263—2269
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Minal Joshi
Peer reviewer comments 2
Editor who approved publication: Dr Katherine Hanlon
Christopher M Aiudi,1 W Michael Hooten,2 Rebecca A Sanders,2 James C Watson,2 Susan M Moeschler,2 Halena M Gazelka,2 Bryan C Hoelzer,2 Jason S Eldrige,2 Wenchun Qu,3 Tim J Lamer2
1Mayo Clinic School of Medicine, 2Division of Pain Medicine, Department of Anesthesia and Perioperative Medicine, Mayo Clinic, 3Department of Physical Medicine and Rehabilitation, Mayo Clinic, Rochester, MN, USA
Objective: Intra-articular injections of the C1–2 joint are an effective therapeutic option for pain generated from degenerative and inflammatory conditions affecting the joint. Limited information exists about the adverse events (AEs) associated with these injections. The primary aim of this study is to describe the frequency and type of AEs associated with C1–2 joint injections. The secondary aim is to identify clinical factors associated with the occurrence of AEs of C1–2 joint injections.
Design/methods: A retrospective chart review was conducted on all C1–2 joint injections performed at the Mayo Pain Medicine Clinic in Rochester, MN, from January 1, 2005 through July 31, 2015. AE data were extracted from procedural and post-procedural clinical notes. Analysis was conducted to determine correlations between any AE and demographic and clinical characteristics. Using univariate and multivariate logistic regression analyses, associations were determined.
Results: From January 1, 2005 to July 31, 2015, 135 C1–2 injections were performed on 72 patients. Overall, at least 1 AE was reported in 18.5% of the injections. The most common AEs were post-procedural increase in pain and procedural vascular contrast uptake. There was a significant association between AE occurrence and greater pre-procedural maximum pain score.
Conclusions: AEs from C1–2 joint injections occurred commonly, but there were no persistent or serious AEs associated with these injections. The data also demonstrate that patients with higher pre-procedural maximum pain scores are more likely to experience an AE.
Keywords: C1–2 joint, facet, injection, adverse event
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]